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ABSTRACT
Heparin-induced thrombocytopenia is an immune-mediated serious adverse effect of heparin 
therapy. It is a relatively frequent complication among patients with mechanical circulatory 
support. Herein, we present a patient with severe heart failure and sepsis who developed hep-
arin-induced thrombocytopenia shortly after implantation of left ventricular assist device as a 
bridge to transplantation and who was successfully treated with fondaparinux. 
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INTRODUCTION
Heparin-induced thrombocytopenia is an immune-mediated serious adverse effect of heparin therapy 
caused by IgG antibodies against heparin/
platelet factor 4 (PF4) complexes, result-
ing in thrombocytopenia associated with 
thromboembolic events. Heparin-induced 
thrombocytopenia is a relatively frequent 
complication among patients with mechanical 
circulatory support and is associated with un-
favorable outcome [1]. Currently, only direct 
thrombin inhibitors (bivalirudin, argatroban, 
lepirudin) are approved by the Food and Drug 
Administration for the treatment of heparin-
induced thrombocytopenia [2]. Herein, we 
present a patient who developed heparin-in-
duced thrombocytopenia shortly after implan-
tation of a left ventricular assist device (LVAD, 
Levitronix CentriMag) who was successfully 
treated with fondaparinux, a synthetic penta-
saccharide factor Xa inhibitor.
CASE REPORT
A 44-year-old man was admitted to our hos-
pital with congestive heart failure. He had 
been treated with optimal medical therapy (ie, 
beta-blocker, ACE-inhibitor, spironolactone, 
loop diuretic, amiodarone, warfarin), but the 
treatment was not successful. Oral antico-
agulant therapy was introduced because of 
severe systolic dysfunction. The patient had 
a long history of idiopathic dilated cardiomy-
opathy and frequent hospitalizations due to 
recurrent acute cardiac decompensation. The 
patient had no other co-morbidities besides 
subclinical hypothyroidism. Unlike previous 
episodes of acute decompensation, when the 
patient presented to our center with volume 
overload, signs of low cardiac output became 
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predominant clinical features. On the second 
day of hospitalization, warfarin was switched 
to enoxaparin because of presumed invasive 
procedures. Echocardiographic examination 
revealed a dilated left ventricle (diameter of 
7.56 cm) with severely impaired systolic func-
tion (ejection fraction of 20%), restrictive dia-
stolic dysfunction and severe mitral regur-
gitation. Electrocardiography showed sinus 
tachycardia (rate of 100–130 beats/min) with 
left anterior hemiblock. The patient developed 
cardiogenic shock, which required intravenous 
inotropic support. Over the next few days, he 
developed sepsis (temperature up to 38.5 ºC, 
C-reactive protein 140 g/L, lymphocyte count 
of 29×109/L with shift to the left) without fo-
cal signs of infection. There was no infiltra-
tion on chest roentgenogram; repeated urine 
and blood cultures were sterile. 
We presumed that low output syndrome and 
visceral hypoperfusion resulted with bacterial 
transudation from the gastrointestinal tract. 
We therefore administered metronidazole and 
gentamicin. However, further hemodynamic 
deterioration with acute kidney and liver fail-
ure occurred. We started dopamine and then 
noradrenaline support. Continuous veno-ve-
nous hemodialysis was also performed due to 
renal failure. The patient responded markedly 
to antibiotics and became afebrile after two 
days. Inflammatory markers decreased and his 
hemodynamic condition became partially sta-
bilized. Kidney and liver function improved, 
though he further needed inotropic and vaso-
pressor support with dobutamine and dopa-
mine. Swan-Ganz catheterization showed very 
low cardiac output (2.56 L/min) and cardiac 
index (1.12 L/min/m2). We concluded that our 
patient needed a mechanical heart support as a 
bridge to heart transplantation. 
He was transferred to the operating room 
and a left ventricular assist device was im-
planted. The procedure was uneventful and 
the patient was anticoagulated with stan-
dard unfractionated heparin. On the fourth 
post-operative day the patient complained of 
sudden shortness of breath without signs of 
pulmonary congestion. The central venous 
pressure increased from 18 to 36 mm Hg; the 
pulmonary artery pressure increased from 
45/30 to 70/50 mm Hg. Echocardiographic 
examination showed a severely dilated and 
hypocontractile right ventricle. The platelet 
count decreased from 190×109/L to 80×109/L; 
D-dimers value was 3 μg/mL. Heparin-in-
duced thrombocytopenia with pulmonary 
embolism was suspected. We could not per-
form pulmonary angiography or scintigra-
phy to confirm the diagnosis, due to techni-
cal difficulties. Unfractionated heparin was 
discontinued and blood sample was drawn for 
enzyme-linked immunosorbent assay (ELISA) 
and micro-typing system assays. For lack of 
other approved anticoagulant drugs for hepa-
rin-induced thrombocytopenia in our hospital, 
fondaparinux (Arixtra) was administered. 
Because the need for anticoagulant therapy 
was urgent, no medical ethical approval was 
obtained. The patient was well informed of the 
situation and signed a consent form to take 
fondaparinux.
We started with initial dose of 7.5 mg of 
fondaparinux; further dose adjustment was 
performed according to anti-Xa assay (target 
levels 0.6–1 U/mL). Both ELISA and micro-
typing system assays were strongly posi-
tive for heparin-induced thrombocytopenia. 
In the next few days after discontinuation of 
unfractionated heparin, the patient’s clini-
cal status improved and platelet count re-
turned back to normal (Fig 1). While on 
fondaparinux, the left ventricular assist device 
did its job with no complications; there was no 
increase in D-dimer or hemolysis. At the time 
of fondaparinux introduction to therapy, the 
patient’s creatinine was 119 µmol/L; his glo-
merular filtration rate (GFR) was estimated at 
61 mL/min/1.73 m2. 
The patient was placed on the Eurotransplant 
waiting list for heart transplantation and 
granted the high urgent status. A donor heart 
was found after 14 days on mechanical cir-
culatory support. Just prior to the operation, 
plasmapheresis was performed and successful 
orthotopic heart transplantation was complet-
ed using unfractionated heparin. Post-trans-
plantation period followed without any com-
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plications. Fondaparinux was discontinued 
after total mobilization of the patient on the 
24th post-operative day. His mean platelet level 
after transplantation and before discharging 
from the hospital was 177.8×109/L (range: 
109–231). During fondaparinux therapy, the 
patient serum creatinine remained normal; 
the estimated GFR improved. The patient was 
discharged from the hospital on the 26th post-
operative day in good clinical condition.
DISCUSSION
Thrombocytopenia is a common labora-
tory finding in critically ill patients. Sepsis 
and hemodilution are two common causes 
of thrombocytopenia, however, heparin-in-
duced thrombocytopenia should also be con-
sidered in the differential diagnosis list [3]. 
Heparin-induced thrombocytopenia usually 
develops 5–10 days after the introduction of 
heparin [1]. It is associated with platelet ac-
tivation and aggregation, endothelial acti-
vation, and thrombin generation with con-
sequential thromboembolic incidents and 
thrombocytopenia. Therefore, platelet count 
should be regularly monitored in patients re-
ceiving heparin. The thrombocytopenia oc-
curs in approximately 3% of those receiving 
unfractionated heparin and in less than 1% of 
those receiving low-molecular weight hepa-
rin [4]. If heparin-induced thrombocytopenia 
is suspected, all heparin products should be 
discontinued and replaced with an alterna-
tive rapid-acting anticoagulant. Currently, 
direct thrombin inhibitors (eg, argatroban, 
lepirudin, bivalirudin) are approved by the 
FDA for the management of heparin-induced 
thrombocytopenia. These drugs have chemi-
cal structures different from unfractionated 
and low-molecular weight heparin and do 
not cross-react with the produced antibodies. 
Some authors hypothesize that fondaparinux, 
which is a selective factor Xa inhibitor with 
a structure of a pentasaccharide chain, is too 
short to induce an antibody response and thus 
could be useful for treating heparin-induced 
thrombocytopenia. 
Fondaparinux is not currently approved 
for the treatment of heparin-induced 
thrombocytopenia; however, it has been used 
in anecdotal case reports [5]. On the other 
hand, there are reports that heparin-induced 
thrombocytopenia could also be related with 
fondaparinux [6, 7]. The development of hep-
arin-induced thrombocytopenia is a major 
clinical problem and is associated with unfa-
vorable outcomes in patients on mechanical 
circulatory support [1]. Arterial and venous 
thromboembolism complicate as many as 50% 
Figure 1: Platelet count and anticoagulant therapy schedule in the patient
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of these cases, and carry 20%–30% mortality 
risk. In accordance with its onset, heparin-
induced thrombocytopenia has different pre-
sentations: a) “classic” or typical onset of hepa-
rin-induced thrombocytopenia with a relative 
decrease in platelet count for ≥50% or absolute 
decrease with <150×109/L within 4–14 days 
of heparin therapy, b) rapid onset of heparin-
induced thrombocytopenia, if the patient has 
antibodies from previous heparin exposure 
(within the past 100 days) when the drop in 
platelet count may begin within 24 hrs after 
heparin initiation, and c) delayed onset of hep-
arin-induced thrombocytopenia that occurs 
several days or sometimes up to three weeks 
after heparin has been discontinued [8]. De-
spite the lack of confirmation by a serotonin-
release functional assay, the “gold standard” 
method with the highest specificity, the diag-
nosis of heparin-induced thrombocytopenia in 
our patient was based on strong clinical and 
laboratory grounds—the patient had a sig-
nificant drop in platelet count four days after 
introduction of unfractionated heparin (ab-
solute platelet count <150×109/L and >50% 
decrease from basal value); he developed a 
thromboembolic event (clinical manifestations 
of pulmonary embolism); he had two different 
positive heparin-induced thrombocytopenia 
serology assays; and his platelet count com-
pletely recovered after discontinuation of 
heparin. Since cardiac transplantation man-
dates the use of unfractionated heparin (at the 
time, other options were not available in our 
institution) there was a question of heparin 
re-exposure. There is published evidence that 
peri-operative plasmapheresis can be used in 
cardiac surgery patients who have a recent 
history of heparin-induced thrombocytopenia 
[9]. We used this approach without further 
complications. Our patient was treated with 
fondaparinux therapy for 10 days and had no 
complications with mechanical circulatory 
support during this period. 
This case demonstrates that fondaparinux 
might be used as an alternative for argatro-
ban, lepirudin, bivalirudin, in patients with 
heparin-induced thrombocytopenia.
To our knowledge, this is the second case re-
port on successful use of fondaparinux in a pa-
tient with heparin-induced thrombocytopenia 
on ventricular assist device [10]. Our case 
showed that fondaparinux could be success-
fully used even in high risk patients with huge 
thrombotic burden and numerous complica-
tions related to multiple organ failure and se-
vere sepsis. 
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